Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk.
Ontology highlight
ABSTRACT: PURPOSE:Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors. METHODS:We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n?=?254 cases and 374 controls), placental growth factor (PlGF, n?=?252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n?=?118 and 240) and steroid hormone concentrations (ALSPAC only, n?=?173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother's birth year, serum/plasma, blood collection timing) and gestational age. RESULTS:Breast cancer ORs (95% CI) were 0.85 (0.51-1.43) for estradiol, 0.86 (0.67-1.09) for testosterone, 0.89 (0.71-1.13) for androstenedione, 0.97 (0.71-1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78-1.27) for PlGF and 1.91 (1.00-3.65 ALSPAC) and 0.94 (0.73-1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis. CONCLUSION:These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.
SUBMITTER: Cornish R
PROVIDER: S-EPMC6438198 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA